

AKR1C2 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP12246B

Product Information

Application	WB, IHC-P, E
Primary Accession	P52895
Other Accession	Q95JH7 , Q04828 , NP_995317.1
Reactivity	Human
Predicted	Monkey
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB32249
Calculated MW	36735
Antigen Region	296-323

Additional Information

Gene ID	1646
Other Names	Aldo-keto reductase family 1 member C2, 1---, 3-alpha-HSD3, Chlordecone reductase homolog HAKRD, Dihydrodiol dehydrogenase 2, DD-2, DD2, Dihydrodiol dehydrogenase/bile acid-binding protein, DD/BABP, Trans-1, 2-dihydrobenzene-1, 2-diol dehydrogenase, Type III 3-alpha-hydroxysteroid dehydrogenase, AKR1C2, DDH2
Target/Specificity	This AKR1C2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 296-323 amino acids from the C-terminal region of human AKR1C2.
Dilution	WB~~1:2000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	AKR1C2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	AKR1C2 {ECO:0000303 PubMed:9716498}
-------------	---------------------------------------

Synonyms

DDH2

Function

Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 3alpha-hydroxysteroids, but also 3beta-, 17beta- and 20alpha-hydroxysteroids (PubMed:[8920937](#), PubMed:[9716498](#), PubMed:[10998348](#), PubMed:[12416991](#), PubMed:[11995921](#), PubMed:[12604236](#), PubMed:[14672942](#), PubMed:[19218247](#), PubMed:[21802064](#), PubMed:[11514561](#), PubMed:[15929998](#), PubMed:[17034817](#), PubMed:[17442338](#), PubMed:[24434280](#)). Required for male sex determination as a component of the 'backdoor' androgen biosynthesis pathway that generates 5alpha-dihydrotestosterone (5alpha-DHT) via pregnanes. Acts together with AKR1C4 to convert 5alpha-dihydroprogesterone (5alpha-DHP) to 3alpha-hydroxy-5alpha-pregn-20-one (3alpha,5alpha-THP/allo pregnanolone), leading to 5alpha-DHT secretion necessary for embryonic gonad differentiation into testis (PubMed:[12416991](#), PubMed:[21802064](#)). In androgen catabolism, may predominantly act as a phase I enzyme by introducing a hydroxyl group prior to conjugation. It can nevertheless participate in the alternative phase II pathway by directly reducing sulfate- or glucuronide-conjugated androgens (PubMed:[10998348](#), PubMed:[11514561](#), PubMed:[14672942](#), PubMed:[15929998](#), PubMed:[19218247](#), PubMed:[24434280](#)). In neurosteroid biosynthesis, may preferentially reduce 5alpha-dihydroprogesterone (5-alpha-DHP) and 5alpha-dihydrodeoxycorticosterone (5-alpha-DHDOC) precursors to 3alpha-hydroxy-5alpha-pregn-20-one (3alpha,5alpha-THP/allo pregnanolone) and 3alpha,21-dihydroxy-5alpha-pregnane-20-one (3alpha,5alpha-THDOC) neuroactive steroids known to alter neural excitability via allosteric activation of gamma-aminobutyric acid type A receptors (GABAAR) (PubMed:[11995921](#), PubMed:[12416991](#), PubMed:[12604236](#)). Regulates ligand availability for steroid hormone receptors. Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstanediols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:[10998348](#), PubMed:[24434280](#)). Can form 17beta-hydroxysteroids such as testosterone and estradiol albeit with lower efficiency when compared to AKR1C3 (PubMed:[10998348](#)). May contribute to the metabolism of adrenal-derived androgens via reduction of 11-keto-5alpha-androstane-3,17-dione (11K-Adione) into 11-ketoandrostosterone (11KAST) and of 11-ketodihydrotestosterone (11KDHT) into 11-keto-5alpha-androstane-3alpha/beta,17beta-diol (11K-A3alphadiol) (PubMed:[31926269](#)). May also play a role in prostaglandin (PG) metabolism by reducing PGD2 to 11beta-PGF2 (PubMed:[9716498](#)). Also able to metabolize xenobiotics (S)-indan-1-ol and trans-1,2-dihydrobenzene-1,2-diols (PubMed:[8573067](#), PubMed:[9716498](#)). In vitro can efficiently catalyze bidirectional conversion between ketosteroids and hydroxysteroids using NADPH/NADP(+) or NADH/NAD(+) as cofactors. In vivo however, the reductase activity prevails since the major reducing cofactor NADPH inhibits NAD(+) dependent oxidase activity (PubMed:[14672942](#), PubMed:[21802064](#)).

Cellular Location

Cytoplasm, cytosol.

Tissue Location

Expressed in fetal testes. Expressed in fetal and adult adrenal glands.

Background

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but

distinct substrate specificity. This enzyme binds bile acid with high affinity, and shows minimal 3-alpha-hydroxysteroid dehydrogenase activity. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14.

References

Setlur, S.R., et al. *Cancer Epidemiol. Biomarkers Prev.* 19(1):229-239(2010)


Wang, X., et al. *PLoS ONE* 5 (8), E11934 (2010) :

Reding, K.W., et al. *Am. J. Epidemiol.* 170(10):1241-1249(2009)


Cogliati, C., et al. *FEBS J.* 276(20):6011-6023(2009)

Davies, N.J., et al. *Cancer Res.* 69(11):4769-4775(2009)

Images



AKR1C2 Antibody (C-term) (Cat. #AP12246b) western blot analysis in HepG2 cell line lysates (35ug/lane). This demonstrates the AKR1C2 antibody detected the AKR1C2 protein (arrow).



AKR1C2 Antibody (C-term) (Cat. #AP12246b) immunohistochemistry analysis in formalin fixed and paraffin embedded human liver tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of AKR1C2 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

Citations

- [Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells.](#)
- [Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.